INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed …
Tag:
Orforglipron
-
-
Lifestyle & Healthslider
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
by Karine Ayoubby Karine Ayoub5 January 2026 — Eli Lilly and Company (NYSE: LLY) today announced positive topline …
-
Lifestyle & Healthslider
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
by Karine Ayoubby Karine AyoubIn ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results …